Director at Solid Biosciences (NASDAQ: SLDB) receives 77,500 stock options grant

Rhea-AI Filing Summary

Solid Biosciences Inc. director Clare Kahn received a grant of stock options to acquire 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no cost as equity compensation.

The option grant was made on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting after the grant date. Any unvested portion will also vest automatically upon specified change in control events.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kahn Clare

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	77,500	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 77,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 77,500 options Exercise price: $6.61 per share Cost to grantee: $0.00 per option +2 more

5 metrics

Options granted 77,500 options Director stock option grant on June 10, 2026

Exercise price $6.61 per share Strike price for director stock options

Cost to grantee $0.00 per option Grant/award acquisition, not open-market purchase

Expiration date June 10, 2036 Option expiration for 77,500-share grant

Shares after transaction 77,500 derivative securities Total derivative options held following the grant

Key Terms

Director Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, change in control events

4 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 6.6100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control events financial

"will vest automatically as to 100% of the unvested portion of such option upon specified change in control events"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kahn Clare

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$6.61	06/10/2026		A		77,500		(1)	06/10/2036	Common Stock	77,500	$0.00	77,500	D

Explanation of Responses:

1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

	/s/ by Kimberly Cornwell as attorney-in-fact for Clare Kahn	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Solid Biosciences (SLDB) director Clare Kahn report on this Form 4?

Director Clare Kahn reported receiving a stock option grant for 77,500 shares of Solid Biosciences common stock. The award is a compensation grant, not an open-market trade, and gives the right to buy shares at a fixed exercise price.

How many Solid Biosciences (SLDB) options did Clare Kahn receive and at what price?

Clare Kahn received options covering 77,500 shares of Solid Biosciences common stock with a $6.61 exercise price. The transaction price per option was $0.00, reflecting a typical director compensation grant rather than a purchase in the open market.

When do Clare Kahn’s Solid Biosciences (SLDB) options vest?

The options granted to Clare Kahn vest in full on the earlier of one year after the June 10, 2026 grant date or immediately before Solid Biosciences’ next annual stockholder meeting. This provides time-based vesting tied to either tenure or the next meeting schedule.

What happens to Clare Kahn’s SLDB options upon a change in control?

Any unvested portion of Clare Kahn’s stock options will vest automatically upon specified change in control events. This means that if qualifying control changes occur, 100% of her then-unvested options would become fully exercisable under the grant terms.

Is Clare Kahn’s Form 4 transaction a buy or sell of SLDB stock?

The Form 4 reflects an acquisition of derivative securities through a grant, not a buy or sell of common stock in the market. The reporting code is “A,” indicating a grant or award of options as compensation rather than an open-market transaction.